Puma Biotechnology, Inc. (NASDAQ:PBYI)
| Market Cap | 499.32M+87.6% |
| Revenue (ttm) | 231.24M-2.9% |
| Net Income | 26.72M-44.9% |
| EPS | 0.52-47.3% |
| Shares Out | 50.90M |
| PE Ratio | 18.30 |
| Forward PE | 49.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,312 |
| Open | 9.55 |
| Previous Close | 9.50 |
| Day's Range | 9.41 - 9.96 |
| 52-Week Range | 4.58 - 10.10 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PBYI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PBYI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PBYI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PBYI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PBYI Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Commercialization | $11.28M | 74.56% |
| Stock-based compensation | $3.85M | 25.44% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PBYI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PBYI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PBYI
| ETF | Est. Holding Size |
|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | $22.77M |
| VTIVanguard Morningstar Total Stock Market ETF | $12.24M |
| IWMiShares Russell 2000 ETF | $11.31M |
| VXFVanguard Extended Market ETF | $4.19M |
| DFATDimensional - US Targeted Value ETF | $3.79M |
| DFASDimensional - US Small Cap ETF | $3.72M |
Estimated from each fund’s disclosed top holdings × AUM
PBYI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PBYI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score